Compare Expedia Group Inc (EXPE) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expedia Group Inc vs Novo Nordisk A/S — how do they compare? Expedia Group Inc trades at $268.54 (market cap $32.06B), while Novo Nordisk A/S trades at $51.57 (market cap $222.24B). The key difference: Novo Nordisk A/S is far larger — about 6.9× Expedia Group Inc's market cap, and Novo Nordisk A/S pays the higher dividend (3.56%). Which is the better fit depends on your goals.
| EXPE | NVO | |
|---|---|---|
Market Cap | $32.06B | $222.24B |
Sector | Consumer Cyclical | Health |
52-Week High | $301.31 | $71.70 |
52-Week Low | $178.06 | $35.29 |
Enterprise Value | $30.97B | $241.20B |
Dividend Yield | 0.66% | 3.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expedia Group (EXPE) trades at $264.76, down 0.57% on the day, with a bullish technical outlook supported by moving averages. The company shows strong fundamentals with revenue growth to $14.73B in 2025 and consistent earnings beats, including Q1 2026 EPS of $1.96 versus $1.41 expected. Recent developments include a strategic partnership with Allegiant Travel and positive analyst coverage highlighting growth potential. Valuation metrics include a P/E of 23.6 and P/S of 2.29, indicating reasonable pricing relative to peers.
The outlook for EXPE is positive, driven by robust travel demand, strategic initiatives, and a consensus price target of $292.09 implying ~10% upside. Key risks include macroeconomic sensitivity affecting travel spending and competitive pressures. Institutional sentiment is bullish with 45% buy ratings, though investors should monitor execution on growth targets and industry cyclicality.
Novo Nordisk (NVO) trades at $51.52, up 4.99% in the last session, with strong technical momentum and bullish moving averages. The company maintains robust fundamentals, including a 37.2% net income margin and consistent earnings beats in recent quarters. Recent EU approval for the Wegovy weight-loss pill (Reuters, 2026-07-15) reinforces its leadership in GLP-1 therapies, though competition is intensifying.
Outlook remains positive given solid cash flow growth and analyst support, but risks include pricing pressure from generics and slowing prescription trends. The stock's valuation at a P/E of 12.14 offers relative value in the pharma sector, with upside potential if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Expedia Group Inc
Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
